

15866 U.S. PTO  
102703

PTO/SB/05 (08-03)

Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	4303-032029
	First Inventor	Jun Tan
	Title	METHODS AND COMPOUNDS FOR DISRUPTION OF CD40R/CD40L SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE
	Express Mail Label No.	EL 970269814US

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents.</i>	<b>ADDRESS TO:</b> Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450
--	---

1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i> 2. <input checked="" type="checkbox"/> Applicant claims small entity status. <i>See 37 CFR 1.27.</i> 3. <input checked="" type="checkbox"/> Specification [Total Pages <input type="checkbox"/> ] <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <input type="checkbox"/> 14] 5. Oath or Declaration [Total Pages <input ]<br="" type="checkbox"/> a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program ( <i>Appendix</i> ) 8. Nucleotide and/or Amino Acid Sequence Submission ( <i>if applicable, all necessary</i> ) a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies
--	--

<b>ACCOMPANYING APPLICATION PARTS</b>	
9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i> 11. <input type="checkbox"/> English Translation Document ( <i>if applicable</i> ) 12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13. <input type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input checked="" type="checkbox"/> Other: <u>Letter Recognizing Attorneys (2 pp.)</u>	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: \_\_\_\_/\_\_\_\_

Prior application information: Examiner \_\_\_\_\_ Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**

<input checked="" type="checkbox"/> Customer Number:	28289	OR <input type="checkbox"/> Correspondence address below
(Insert Customer No. or Attach bar code label here)		

Name	Barbara E. Johnson				
	Webb Ziesenheim Logsdon Orkin & Hanson, P.C.				
Address	700 Koppers Building				
	436 Seventh Avenue				
City	Pittsburgh	State	PA	Zip Code	15219
Country	United States	Telephone	412-471-8815	Fax	412-471-4094

Name (Print/Type)	Barbara E. Johnson	Registration No. (Attorney/Agent)	31,198
Signature	<i>Barbara E. Johnson</i>	Date	October 27, 2003

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

{W0087860.1}

17510 U.S. PTO  
 10/694634  
 10/27/03  
 The PTO did not receive the following listed item(s) 4 pages drawing

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

ATTORNEY'S DOCKET NUMBER

Jun Tan

4303-032029

ENTITLED

METHODS AND COMPOUNDS FOR DISRUPTION OF CD40R/CD40L SIGNALING IN  
THE TREATMENT OF ALQHEIMER'S DISEASE

Mail Stop Patent Application  
P.O. Box 1450  
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number EL 970269814 US

Date of Deposit October 27, 2003

I hereby certify that the following enclosed papers or fees:

Letter Recognizing Attorneys (2 pp.)  
Utility Patent Application Transmittal Letter (original and two (2) copies);  
Specification (43 pp.), Claims (18 pp.) and Abstract (1 p.); and  
Sheets of drawings (14 pp.)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Helen Gerace

(Typed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : Not Yet Assigned

Applicants : Jun Tan, Terrence C. Town, and  
Michael Mullan

Filed : Filed Concurrently Here

Title : METHODS AND COMPOUNDS FOR  
DISRUPTION OF CD40R/CD40L  
SIGNALING IN THE TREATMENT OF  
ALZHEIMER'S DISEASE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

LETTER RECOGNIZING ATTORNEYS

Sir:

Enclosed for filing is an informal application for patent as above identified,  
comprising a specification, claims, abstract and drawings.

Information regarding the inventors and the application is as follows:

1. Inventors:

Jun Tan  
Bradenton, Florida 34243;

Terrence C. Town  
Bradenton, Florida 34243; and

Michael Mullan  
Bradenton, Florida 34243.

2. Citizenship:

Jun Tan, Chinese citizen;

Terrence C. Town, United States of America citizen; and

Michael Mullan, United Kingdom citizen.

3. Title: METHODS AND COMPOUNDS FOR DISRUPTION OF CD40R/CD40L SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE
4. Priority: United States Provisional Application Serial Number 60/421,338, filed October 25, 2002.
5. Drawings: 14 sheets of drawings containing 61 figures
6. Claims: 92 claims
7. Small Entity: Small Entity Status is asserted for this application under 37 CFR 1.27.


Please accept the application for purposes of granting a filing date pursuant to 37 C.F.R. §1.53(b) and recognize Barbara E. Johnson, Registration No. 31,198; Russell D. Orkin, Registration No. 25,363; Gwen R. Wood, Registration No. 51,027; and Patricia A. Olsky, Registration No. 53,411 as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney and payment of the filing fee. 37 C.F.R. §1.53(b).

Kindly direct all communications relating to this application to Russell D. Orkin.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON  
ORKIN & HANSON, P.C.

By



Barbara E. Johnson  
Registration No. 31,198  
Attorney for Applicants  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, PA 15219-1818  
Telephone: 412-471-8815  
Facsimile: 412-471-4094  
E-mail: [webblaw@webblaw.com](mailto:webblaw@webblaw.com)